Board Of Directors

Bob Carpenter, MS, MBA

Co-Founder and Board Member

Bob Carpenter, MS, MBA

Co-Founder and Board Member

Mr. Carpenter is a leader and pioneer in the healthcare and biotechnology industries. He served on Genzyme’s Board of Directors from 1994-2011 and was Executive Vice President of Genzyme from 1989-1991 as well as chairman of its subsidiary IG Laboratories. He founded and served in executive management and board roles at numerous biotech companies, including Integrated Genetics and GelTex Pharmaceuticals, both of which merged with Genzyme, and VacTex, which was acquired by Aquila Biopharmaceuticals. Mr. Carpenter is currently chairman of Hydra Biosciences. Mr. Carpenter is a graduate of West Point. He earned his masters in computer science from Stanford University and his MBA from Harvard Business School.

Ben Zeskind, PhD, MBA

Co-Founder and CEO

Ben Zeskind, PhD, MBA

Co-Founder and CEO

Dr. Zeskind co-founded Immuneering in 2008 with the goal of leveraging high-throughput data to improve pharma R&D. He is an inventor on numerous patents assigned to both Immuneering's partners and the company itself, and has published extensively in peer-reviewed journals. He trained at the Massachusetts Institute of Technology, earning a Ph.D. in Bioengineering in 2006 and an S.B. in Electrical Engineering and Computer Science in 2003. He also earned an MBA at Harvard Business School in 2008, where he was recognized as a Baker Scholar, the highest award for distinction.

Scientific Advisory Board

Doug Lauffenburger, PhD, Professor of Biological Engineering, MIT

Co-chair, Scientific Advisory Board

Doug Lauffenburger, PhD, Professor of Biological Engineering, MIT

Co-chair, Scientific Advisory Board

Dr. Lauffenburger is the head of the Department of Biological Engineering at the Massachusetts Institute of Technology and a pioneer in applying engineering principles to biological research. His expertise spans multiple disciplines including chemical engineering, bioengineering, biotechnology process engineering, biophysics, quantitative cell and structural biology, systems biology, and applied mathematics. He has filed numerous patents, authored a key textbook on receptor-ligand binding and trafficking dynamics, and published more than 200 peer-reviewed articles.

Max Artyomov, Ph.D., Assistant Professor of Immunology and Pathology, Washington University

Co-chair, Scientific Advisory Board

Max Artyomov, Ph.D., Assistant Professor of Immunology and Pathology, Washington University

Co-chair, Scientific Advisory Board

Dr. Artyomov is an Assistant Professor of Immunology and Pathology at Washington University in St. Louis. His research is focused on developing an integrated experimental and computational pipeline to address important biological problems by leveraging the power of next-generation sequencing. His approach combines the power of systems immunology with high-throughput sequencing, mathematical modeling and statistical physics. Dr. Artyomov conducted his postdoctoral research at the Broad Institute of Harvard and MIT and earned a Ph.D. in chemistry at the Massachusetts Institute of Technology, with a focus on computational immunology.